Risk frame
Three risk patterns dominate. Theft and diversion in transit and at warehouse breakpoints. IP and competitive intelligence at research and clinical sites — the buyer is often a state actor or contracted intermediary. And third-party governance — a contractor incident at a clinical site is the sponsor's regulatory exposure.
Compliance: EU GDP for distribution, GMP for manufacturing, EU CTR for clinical trials, and GDPR for clinical and patient data. Suppliers must integrate into the operator's quality system, not stand alongside it.
Service fit
- Secure logistics for high-value goods. Documented chain-of-custody, vetted drivers, route engineering, and tamper-evident handling for pharma, biological samples, and controlled substances in transit.
- Site and lab security. Static officers and access-control protocols for research, manufacturing, and clinical-trial sites — paired with TSCM where IP-sensitive meetings or boardrooms require it.
- Background screening and due diligence. Pre-employment screening, contractor vetting, and pre-engagement due diligence aligned with sponsor and regulator expectations.
Example case patterns
- Cold-chain transit programme. A specialty-pharma operator integrated a documented chain-of-custody and tamper-evident protocol into its EU distribution. Audit findings on supplier governance dropped to zero across two cycles.
- Boardroom IP protection. A biotech mid-cap layered TSCM sweeps and visiting-principal protocols into board cycles ahead of M&A discussions. No surprises followed; the engagement closed under target leak risk.